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Abstract: Angelman syndrome (AS, MIM 105830) is a rare neurodevelopmental disorder affecting
1:10–20,000 children. Patients show moderate to severe intellectual disability, ataxia and absence of
speech. Studies on both post-mortem AS human brains and mouse models revealed dysfunctions
in the extra synaptic gamma-aminobutyric acid (GABA) receptors implicated in the pathogenesis.
Taurine is a free intracellular sulfur-containing amino acid, abundant in brain, considered an inhibiting
neurotransmitter with neuroprotective properties. As taurine acts as an agonist of GABA-A receptors,
we aimed at investigating whether it might ameliorate AS symptoms. Since mice weaning, we orally
administered 1 g/kg/day taurine in water to Ube3a-deficient mice. To test the improvement of motor
and cognitive skills, Rotarod, Novel Object Recognition and Open Field tests were assayed at 7, 14,
21 and 30 weeks, while biochemical tests and amino acid dosages were carried out, respectively,
by Western-blot and high-performance liquid chromatography (HPLC) on frozen whole brains.
Treatment of Ube3am−/p+ mice with taurine significantly improved motor and learning skills and
restored the levels of the post-synaptic PSD-95 and pERK1/2-ERK1/2 ratio to wild type values.
No side effects of taurine were observed. Our study indicates taurine administration as a potential
therapy to ameliorate motor deficits and learning difficulties in AS.
Keywords: Angelman syndrome; taurine oral administration; motor and learning recover of deficit
1. Introduction
Angelman syndrome (AS, MIM 105830) is a rare neurodevelopmental disorder affecting
1/10–20,000 children. The majority of AS patients share a moderate to severe development delay and
intellectual disability, movement disorders and ataxia of gait, absence or limited speech and a peculiar
behavior characterized by happy disposition, hyperexcitability and hand flapping, while over 80% of
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cases have relative microcephaly, seizures and a specifically altered EGG pattern with large-amplitude
slow spike waves, sleep disorders [1,2]. Patients show a peculiar facies with prognathism, wide spaced
teeth, pale skin and hair, addressing the clinical suspicion, but overall clinical manifestations are highly
heterogeneous, partially depending on the specific molecular defects causing the disease. Figure 1
shows AS children at different ages and genetic defects evidencing the AS facies and its variability.
Figure 1. A photograph of AS patients representative of the genetic mechanisms: (a) deletion of
15q11–12; (b) chr.15 paternal uniparental disomy; (c) imprinting centre; (d) UBE3A point mutations.
All patients’ parents have signed the informed consent.
Genetic etiology consists of the lack of function of the maternal allele of UBE3A gene,
mapping·within the imprinted chromosomal region 15q11.2–q13 and coding for the E3 ubiquitin
protein ligase involved in the ubiquitination of targeted proteins via proteasome degradation.
Expressed in multiple cell compartment, UBE3A regulates oxidative metabolism in mitochondria, gene
transcription in euchromatin-rich nuclear domains and might be involved in synaptic plasticity [3].
A paternally neuron specific long antisense transcript prevents the transcription of the paternal UBE3A
allele, so in neurons, in spinal cord and peripheral nerves only UBE3A maternal allele is expressed [4].
Four molecular classes of defects impair UBE3A functionality: deletions encompassing the gene on
the maternal allele (70% of cases), paternal uniparental disomy of chromosome 15q (3–5%), altered
methylation at Imprinting Centre (3–5%) and point mutations within UBE3A coding sequence in up
to 11%. Ube3a deficient mouse model [5] display phenotypes correlating with the human disorder,
recapitulate features as motor deficits, learning and memory impairment, with differences depending
on the strains. They greatly contributed to understand the molecular and cellular mechanisms involved
in the pathophysiology of the disorder [6]. The potential dysfunction of GABAergic inhibitory system
in Angelman syndrome has been investigated in animal model and in AS postmortem human brains
revealing alterations that predict impairment of cortical extrasynaptic, but not synaptic GABAergic
activity [7]. AS model mice also exhibit an increase in hippocampal mitochondrial reactive oxygen
species which may contribute to the behavior deficit [8–10]. At the moment no efficacious therapy
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has been developed and the restoration of GABAergic neuronal function appears one of the most
direct strategies to treat epileptic and neurological traits [11]. Administration of selective extrasynaptic
GABA receptors agonist seems to ameliorate motor dysfunction in AS [12].
Taurine (2-β aminoethansulphonic acid) is a free intracellular sulfur-containing amino acid
characterized by the presence of a sulfonate instead of a carboxyl group, not incorporated in proteins
and representing the second most abundant amino acid in Central Nervous System (CNS) [13].
In human, taurine biosynthesis occurs primarily in the liver, but it may be consumed through
food, mainly meat and seafood [14]. In CNS it exerts roles in cell volume regulation and in
neurotransmission. Recently, various studies evidenced that taurine plays a neuroprotective role
for CNS [15–17] and it is involved in neurogenesis [18]. Essential for the neuroprotection is its role in
opening inhibitory anionic channels by activating glycine and/or non-synaptic GABA-A receptors [19].
Reyes-Haro et al. (2014) [20] showed taurine acts as weak agonist of GABA-A receptors in astrocytes
and in STC-1 (Secretin tumor cell lines), cells expressing various GABA-A subunits.
On the basis of this evidence we designed the present study to investigate the efficacy of taurine
administration to Ube3am−/p+ mice in ameliorating their motor and learning dysfunction. Basing on
reports showing that taurine, chronically administered both in food [21] or in drinking water [15,22,23]
ameliorated motor and/or cognitive deficits of syndromic disorder, we orally administered 1 g/kg/day
weight. A similar dosage has already been demonstrated successful and not toxic in a mouse model
of Alzheimer’s disease [15]. Considering that the rescue of AS neurocognitive deficits achieved best
results in an AS inducible mouse, when UBE3A was reactivated at three weeks [24], we chose to start
taurine administration at the 21st day, just after weaning.
2. Results
Therapeutic effect of oral and chronic administration of taurine in motor impairment and learning
difficulties of Angelman syndrome was examined administrating a battery of three behavioral tests
to the transgenic Ube3am−/p+ on the C57BL/6 background. Eight different experimental groups of
animals were considered: untreated (1) male and (2) female Ube3am−/p+; treated (3) male and (4) female
Ube3am−/p+; untreated (5) male and (6) female wild type Ube3am+/p+ (wt) and treated (7) male and
(8) female Ube3am+/p+ wt.
2.1. Taurine Ameliorates Motor Coordination of Ube3am−/p+ Mice
To identify differences in motor coordination, all the test groups were assayed through rotarod
tests at four development time points: 7, 14, 21 and 30 weeks after birth. As showed in Figure 2,
comparison between groups, untreated Ube3am−/p+ versus untreated wt mice, showed a significant
impairment in rotarod performance (all time points: *** p < 0.001), while Ube3am−/p+ mice administered
with taurine since weaning showed a heterogeneous but significant amelioration. The only exception
was observed for Ube3am−/p+ male group at 30 weeks, showing no significant improvement.
No significant effect was observed in controls after taurine treatment.
2.2. Open Field Test Reveals a Partial Improvement upon Taurine Administration
The open field test (OFT) was used to evaluate locomotor activity, anxiety and exploration
behavior in our groups: total distance, distance travelled in the center zone and number of rearings
were then taken into account. Analysis of these parameters obtained by the ANY Maze software,
indicated a behavioral deficit in the untreated Ube3am−/p+ versus untreated wt mice as revealed by
the significant reduction of all observed OFT parameters (Figure 3). Since the 14th week, a significant
decrease in total distance was observed (in both males and females) (Figure 3a—left and right panels),
but it was more evident in females. Similarly, the significant differences in distance traveled in the
central area as well as rearing number were more pronounced in females and became evident since the
7th week of life (Figure 3b,c—right panels).
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Figure 2. Taurine treatment improved motor coordination in AS (Ube3am−/p+) mice. Rotarod tests
were carried out at four time points (7, 14, 21 and 30 weeks) on wild type (wt) and Ube3am−/p+ mice
(both treated (taurine) and untreated (vehicle)). Analyses were conducted by separating genders
(male: left panel; female: right panel). Animals per group: male mice (wt + vehicle = 14, wt + taurine = 12,
Ube3am−/p+ + vehicle = 11, Ube3am−/p+ + taurine = 11); female mice (wt + vehicle = 15, wt + taurine = 13,
Ube3am−/p+ + vehicle = 12, Ube3am−/p+ + taurine = 14). Data are shown, for each time point,
as media ± SEM. Effect of genotype: *** p < 0.001; effect of taurine treatment on Ube3am−/p+ genotype:
# p < 0.05, ### p < 0.001.
Taurine treatment showed a beneficial effect mainly in female Ube3am−/p+ mice: a significant
increase in locomotor activity was observed at the 14th and 21th week (### p < 0.001) (Figure 3a—right
panel). Taurine-treated Ube3am−/p+ males showed a partial but not significant rescue of locomotor
performances (Figure 3a—left panel). Similarly, differences between genotypes in central area distances
(Figure 3b—right panel) and rearing number (Figure 3c—right panel) were partially restored by taurine
at the 14th and 21th week in Ube3am−/p+ female group (# p < 0.05; ## p < 0.01). A partial restore was
also noted in males group, at the 7th week for central square distance (Figure 3b—left panel) and at
the 30th week for rearing number (Figure 3c—left panel). For all parameters, no significant effect of
taurine was observed in wt animals.
From a longitudinal view, a general flexion in measured parameters was observed in almost all test
groups from the first time point (7th week) to other time points (14th and/or 21th and/or 30th week).
2.3. Learning and Memory Deficits Improve in Ube3am−/p+ after Taurine Administration
Novel object recognition test (NORT) was used to measure visual recognition memory and anxiety
level in Ube3am−/p+ mice along with Ube3am+/p+ controls. Mice show an innate and natural ability to
explore unfamiliar objects: low levels of exploration may correlate with a state of anxiety. Locomotor
activity should be carefully monitored but is not a critical element that can invalidate the effectiveness
of the NORT [25]. Hyperdinamic and non-interacting mice have been discarded or retested. Evaluation
of recognition index (RI) (Figure 4) revealed a strong genotype effect (Ube3am−/p+ vs. wild type)
evidencing, for both males and females, at each time point, a very limited skill to explore the unfamiliar
object (*** p < 0.001). Ube3am−/p+ mice administered with taurine ameliorated their propensity for
exploration: Ube3am−/p+ male mice at the 21th and 30th weeks (### p < 0.001); Ube3am−/p+ female
mice at the 7th (# p < 0.05), 21th (### p < 0.001) and 30th (# p < 0.01) weeks. Surprisingly, at the 30th
week Ube3am+/p+ female mice manifested a slight and borderline decrease in novel object preference.
Longitudinal analyses highlighted, for both genders, the maximum improvement in the 30th week.
2.4. Effect of Taurine on Synaptic Markers
To investigate if taurine administration may restore the synaptic deregulations pointed out by
studies on AS patients [26–28], the level of the PSD-95, and the ratio between pERK1/2 and total
ERK1/2 were investigated by Western blot in total brains from 30-week-old animals. As shown in
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Figure 5a,b, a slight increase of total PSD-95 (black bar) and activation of the ERK1/2 ratio (black bar)
was found in transgenic mice. Taurine administration to transgenic mice restored values to wild type
levels (red bar). Consequently, another member of MAPK signaling, transducing extracellular stimuli
in intracellular cascade, JNK (c-Jun N-terminal kinase) was assayed showing a normal pJNK/JNK
ratio in Ube3am−/p+ whole brain.
Figure 3. Taurine administration partially improved locomotor activity, anxiety and exploration in AS
female (Ube3am−/p+) mice. Open field assay was carried out at four time points (7, 14, 21 and 30 weeks)
on wild type (WT) and Ube3am−/p+ mice (both treated (taurine) and untreated (vehicle)) by measuring
(a) total distance traveled (m); (b) distance in center square (m) and (c) number of rearings. Analyses
were conducted by separating genders (male: left panels; female: right panels). Number of animals per
group: male mice (wt + vehicle = 13, wt + taurine = 12, Ube3am−/p+ + vehicle = 11, Ube3am−/p+ + taurine
= 12); female mice (wt + vehicle = 13, wt + taurine = 13, Ube3am−/p+ + vehicle = 11, Ube3am−/p+ + taurine
= 13). Data are shown, for each time point, as media ± SEM. Effect of genotype: * p < 0.05, ** p <0.01,
*** p < 0.001; effect of taurine treatment on Ube3am−/p+ genotype: # p <0.05, ## p <0.01, ### p < 0.001.
2.5. Taurine Content in Brain and Serum
We examined if the daily consumption of taurine in water altered the taurine content in serum
and in whole brain. As shown in Figure 6, there were no differences in taurine level between untreated
transgenic and wild type mice. A significant increase was observed in serum, where treated mice,
independently from genotype, showed a taurine concentration 4–6-fold higher (Figure 6a). Conversely,
the measurements of taurine in brain were similar in all tested groups (Figure 6b), according to the
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regulation of brain concentration by an active TauT transporter [16,29]. Quantification of additional
neurotransmitters as Glutamic acid, GABA and Glutamine did not show significant differences
(Appendix A, Figure A1).
Figure 4. Taurine treatment improved learning and memory in AS (Ube3am−/p+) mice. Novel object
recognition test was carried out at four time points (7, 14, 21 and 30 weeks) on wild type (WT)
and Ube3am−/p+ mice (both treated (taurine) and untreated (vehicle)). Analyses were conducted by
separating genders (male: left panel; female: right panel). Number of animals per group: male mice
(wt + vehicle = 14, wt + taurine = 11, Ube3am−/p+ + vehicle = 14, Ube3am−/p+ + taurine = 13); female
mice (wt + vehicle = 12, wt + taurine = 14, Ube3am−/p+ + vehicle = 12, Ube3am−/p+ + taurine = 14).
Data are shown, for each time point, as media ± SEM. Effect of genotype: *** p < 0.001; effect of taurine
treatment on Ube3am+/p+ genotype: § p < 0.05; effect of taurine treatment on Ube3am−/p+ genotype:
# p < 0.05, ## p < 0.01, ### p < 0.001.
Figure 5. Activation of pERK1/2-ERK1/2 signaling and altered level of PSD-95 restored by taurine
administration. Panel (a) Representative Western blots from female total brain homogenates show
the expression of UBE3A (top blot), PSD-95, phosphorylated ERK1/2 and total ERK1/2 proteins,
normalized by GADPH. m−/p+ (for Ube3am−/p+) and m+/p+ (for Ube3am+/p+) indicate the respective
genotypes; the signs just below are referred to the treatment: + for taurine administration and—for
vehicle. Panel (b) mean of scaled density values obtained from 3 independent experiments are showed.
Significant differences between groups and untreated control are displayed with asterisks (* p < 0.05,
** p < 0.01).
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Figure 6. Blood serum Panel (a) and whole brain Panel (b) content of taurine evidenced a different
accumulation in the two tissues. Measurement of taurine levels in blood serum and in whole brain of
mice evaluated by high performance liquid chromatography. Asterisks indicate significant differences
(* p < 0.05, ** p < 0.01). Number of mouse blood serums: wt + vehicle = 8, wt + taurine = 10,
Ube3am−/p+ + vehicle = 6, Ube3am−/p+ + taurine = 6. Number of mouse brains: wt + vehicle = 13,
wt + taurine = 8, Ube3am−/p+ + vehicle = 7, Ube3am−/p+ + taurine = 9.
3. Discussion
Angelman syndrome is a rare disorder severely affecting AS probands’ and their parents’ quality
of life. Cognitive impairment, ataxic gait, absence of speech and occurrence of seizures are the main
features of the syndrome that no therapy is available to ameliorate.
Our study reports that taurine dissolved in drinking water may restore motor deficits and
learning impairment of a Ube3am−/p+ C57BL/6J mouse when administered daily, while the same
treatment has no effect on motor and cognitive behavior of a wild type Ube3am+/p+ mouse. As the best
period to obtain a rescue of behavioral deficits in the AS model seems to be the postnatal period [24],
we started the treatment in the juvenile period of life (three weeks) as soon as the pups were able to
feed by themselves. During the statistical evaluation, genders were considered separately to ensure
a better homogeneity in the test groups and the amelioration appeared substantially overlapping,
with the exception of the Open Field test. The rescue of motor deficit demonstrated by rotarod assay
appeared since the first set of tests at the 7th week suggesting a strong effect of taurine on these skills;
this point is supported by the performances at total distance walked in the OF test, a measure of
ataxia attenuation, with significant improvement in the female group and a trend to improvement
in males. A slight decrease of female performance at the last time-point may suggest that dosage
could need to be adjusted during such a long chronic treatment. Variations among sex might be
due to some environmental factors, as reported by Kovacs [30] in C57BL/6J mice. Memory and
learning skills, as shown by NORT, results raised toward those of control animals, since the last
two sets of evaluations, indicating the need of a longer treatment to achieve visible improvement of
learning disability. Apparently, the prolonged administration of 1 g/Kg/day taurine did not reveal
any toxicity [15]. Taurine is well known to increase neurogenesis of adult neural stem cells [18,31]
and to promote neuroprotection preventing (i) glutamate-induced excitotoxicity through modulation
of intracellular calcium homeostasis [32]; (ii) mitochondrial dysfunction by exerting an antioxidant
activity; and (iii) apoptosis, by downregulating molecules that drive apoptotic events [16,17,33,34].
Potential beneficial effects of taurine in brain disorders, as Alzheimer’s [15], schizophrenia [16] and
neurodevelopment disorder as fragile X syndrome have been reported [23,35]. Out of the multiple
functions of taurine in the mammalian body, a key one is modulation of GABA neurotransmission.
A defect in tonic GABAergic inhibition shared by fragile X and Angelman syndrome has been suggested
to contribute to expression of the disease phenotype [11], raising the option to use agonists of GABA
receptors as a winning strategy to restore the decrease in GABAergic inhibition [12]. Interestingly,
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taurine is considered an endogenous ligand of GABA extrasynaptic receptors [36]. Our study first
investigates and proves the beneficial effect of taurine administration in ameliorating AS features
of Ube3am−/p+ mice supporting the concept that GABA receptor agonist strategy may be effective.
Neurological deficits in Angelman syndrome have been associated with an increased level of Arc
(activity-regulated cytoskeletal-associated protein) which has the consequence to impair the Long Term
Potentiation (LTP) and alter the recruitment of the scaffold protein PSD-95 (PostSynaptic Density-95),
a marker of synaptic dysfunction [26]. Furthermore, UBE3A loss enhances the ERK1/2 (Extracellular
Signal-Regulated Kinase) signaling pathway [27], which plays a relevant role in several biological
processes including synaptic activity with a stimulatory effect on the proliferation of neural stem cells
rather than in the following differentiation [37]. Our biochemical analyses confirmed the activation
of ERK1/2 pathway and a major expression of the synaptic protein PSD-95 as a consequence of
UBE3A deficit in the Ube3am−/p+ mice and demonstrated that taurine may restore a normal activity
of both markers. We could speculate that the therapeutic effect of taurine in the AS model might be
achieved for a restoration of both extrasynaptic GABAergic activity, with taurine being an agonist
of the GABA receptor, and synaptic pathway as shown by our data on ERK1/2 activity and PSD-95.
The dosage of taurine in the whole brain remained the same in treated and untreated animals while in
serum we observed an a 4–6 folds increase. This finding is not completely unexpected considering the
occurrence of active transport of taurine in brain, mediated by a specific saturable TauT transporter [16].
Sved D.W. et al. [29] investigated the absorption and tissue distribution when taurine was orally
administered to rats using 14C taurine and observed that some tissues as brain, heart, muscles showed
a slow increase of 14C taurine during the first 24 h and a small decrease during the following 168 h
without changing the total amount of brain taurine. The authors supposed that after taurine passed
the blood–brain barrier (BBB), it became part of an endogenous pool regulated by a Na+/Cl− saturable
transport within brain cells, which makes the taurine concentration in brain not proportional to plasma
concentration. The same behavior has been described in muscles where despite a very high dosage of
taurine being administered to a Duchenne dystrophy model, high performance liquid chromatography
(HPLC) quantification revealed a higher concentration only in serum and in liver [38], while muscles
maintained a constant concentration.
4. Materials and Methods
4.1. Animals
All subjects were heterozygous mice with deficiency of Ube3a on the maternal allele (Ube3am−/p+)
and wild type (Ube3am+/p+) littermates, on the C57BL/6J background. Mice, developed by the Beaudet
laboratory [39], were acquired from Charles River laboratories. Heterozygous Ube3am−/p+ females were
crossed with wild type males (Ube3am+/p+) to generate Ube3am−/p+ as well as wild type mice. The 21th
day after birth, the animals were weaned and genotyped by PCR (from tail tissues), as described in [39].
Animals were bred with a regular 12:12 h light/dark cycle (lights on 07:00 a.m.), at a constant room
temperature of 22 ± 2 ◦C, and relative humidity approximately 55 ± 10%. Animals were housed (n = 4
per group) in standard mouse cages. All mice were provisioned with bedding material (hard wood
shavings), ad libitum food (Global Diet 2018S, Harlan Italy) and water. All procedures involving
animals and their care were conducted in strict compliance with the national and international laws
and policies and approved by the University of Study of Milano Animal Care and Use Committee
(IACUC) (Approval Number: 95/14; Approval Date: 27 March 2014).
4.2. Tissue Collection
After behavioral experiments, mice at the 7th and 30th weeks were euthanized by cervical
dislocation and the brains were immediately frozen in dry ice and stored at−80 ◦C prior to biochemical
and immunohistochemical processing.
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4.3. Taurine Administration
Taurine was orally administered via drinking water at dose level of 1000 mg/kg/day from weaning
to 30 weeks of age. Taurine-based solution was prepared fresh twice a week adjusting volumes and
amount of dissolved taurine for body weight changes and water intake Body weights were monitored
twice a week for all the treated groups. To ensure the mice received the right dose required by the
protocol, the effective amount of taurine intake was inspected every day for each cage. The animals did
not suspend the taurine administration before tests, apart from the time they were trained or tested.
4.4. Test Groups
Four groups were considered for tests. Group 1: Ube3am+/p+ received drinking water only (control);
Group 2: Ube3am+/p+ received taurine; Group 3: Ube3am−/p+ received drinking water only; Group 4:
Ube3am−/p+ received taurine. Males and females were statistically analyzed separately.
4.5. Behavioral Tests
Tests were performed at 7th, 14th, 21th and 30th week of life. The equipment (e.g., open field
arena) and all objects directly interacting with animals were cleaned using 70% ethyl alcohol to
eliminate distracting/confounding olfactory stimuli.
4.5.1. Rotarod
Mice were tested for balance and motor coordination by using an accelerating Rotarod (Ugo Basile
7650 model). Animals were initially trained for 4 sessions at a constant speed of 4 rpm: when properly
trained they were tested twice (a 5 min-test) on a gradually accelerating rotarod (0.3 rpm/s increase
from 3 to 300 rpm) by measuring the latency to fall from the bar (seconds). The final score was
determined as the average of 2 trials.
4.5.2. Open Field (OF) and Spontaneous Locomotor Activity
The open field test evaluates general locomotion activity, exploration behavior and level of anxiety
by exposing mice to a novel and open space [40]. We used a 40 cm× 40 cm× 40 cm grey arena divided
into 25 equal squares by black lines. During test, noises and lighting were consistently attenuated
in order not to create artificial/external stress to mice. Mice were placed into the center of the floor
defined as a “starting point” and allowed to explore for 5 min. Tests were video-recorded by a camera
apparatus. Test parameters were obtained via the automated ANY-maze Behavior Tracking Software
(Stoelting Co., Wood Dale, IL, USA). Total distance, distance in central square and number of rearings
were taken into account.
4.5.3. Novel-Object Recognition Test (NORT)
The novel-object recognition test (NORT) is a memory test relied on spontaneous animal
behavior [41,42] aimed to exploit the natural exploration attitudes of mice. In the present study,
tests were conducted in an open-field arena (40 cm × 40 cm × 40 cm) divided into 25 equal squares
by black lines. The first day (day 1), animals were habituated for five minutes in a clean and empty
arena: their movements were recorded as the number of line crossings, which provided an indication
of both wild type and transgenic mice locomotion motor activities. In the next day (day 2), mice were
re-placed in the same arena containing two identical objects (familiarization phase), randomly selected
from a group of specific objects (a red rubber cylinder (4 cm × 5 cm), a plastic vial with a white cup
(3 cm × 6 cm) and a plastic cube (3 cm × 5 cm)) to avoid bias among animals and between groups.
Exploration was recorded in a 10 min trial by an investigator blinded to the genotype and treatment.
In the familiarization phase, the time spent exploring the two identical objects (e.g., sniffing, touching,
and stretching—at a minimum distance of 2 cm) was recorded and evaluated as object investigation.
The test day (day 3), mice were still placed in the arena and exposed for 5 min to two different
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objects: one exposed during the familiarization phase, while the second one was something absolutely
unfamiliar. As described above, time spent interacting with both objects was recorded and evaluated.
A cut-off of 6 s was applied to the total exploration time (both during the familiarization and test
phases): tests not meeting the minimum threshold were discarded. Recognition Index (RI), expressed
as time spent exploring the novel object (TN) with respect to the total time spent exploring both objects
(TN + TF) was estimated.
4.6. Western Blotting
Approximately 200 mg of brain tissue, were rapidly homogenized in ice-cold lysis buffer
(Sucrose 0.32 M, Hepes 10 mM pH 7.4, PMSF 0.1 mM, NaHCO3 1 mM, in presence of proteinase and
phosphatase inhibitors, Complete Mini and PhosSTOP—Roche, Basel, Switzerland) using a mechanical
homogenizer (Euro Turrax T20b, Ika Labor Technik, Staufen im Breisgau, Germany) at 27,000 rpm for
1 min, holding the sample on ice. Total homogenates were clarified by centrifugation at 1000× g for
5 min at 4 ◦C to remove crude nuclear material (P1). The supernatant (S1) was assayed for total protein
content using a commercial protein assay kit according to manufacturer’s protocol (DC Protein Assay
Kit—BioRad, Hercules, CA, USA).
Samples containing 30 µg proteins were resolved in 8% sodium dodecyl sulphate-polyacrylamide
gels under reducing conditions and transferred to nitrocellulose membranes (iBlot Gel Transfer
Stacks Nitrocellulose—Invitrogen, Carlsbad, CA, USA). Membranes were blocked for 1 h at room
temperature in 5% milk solution, TBS (Tris-NaCl, pH 7.5) and tween 0.1% (TBT-T) and, then incubated
with primary antibodies UBE3A (1:500; polyclonal; Proteintech Group, Rosemont, IL, USA), PSD-95
(1:1000; monoclonal; Millipore, Burlington, MA, USA), p44/42 MAPK (Erk1/2) (1:2000; polyclonal;
Cell Signaling Technology, Danvers, MA, USA), Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)
(1:2000; monoclonal; Cell Signaling Technology), SAPK/JNK (1:1000; polyclonal; Cell Signaling
Technology), Phospho-SAPK/JNK (1:1000; polyclonal; Cell Signaling Technology) and GAPDH
(1:1500; polyclonal; Santa Cruz Biotechnology, Dallas, TX, USA) at 4 ◦C overnight in 5% milk TBS-T
solution. Subsequently, membranes were washed and incubated for 1 h at room temperature in
5% milk, TBS-T solution with peroxidase-conjugated anti-rabbit or anti-mouse immunoglobulin G
(Millipore) as secondary reagents. After washing with TBS-T, membranes were treated with ECL
(Novex ECL Chemiluminescent Substrate Reagent Kit, Invitrogen). X-ray films were exposed in a linear
range. Bands were quantified by using ImageJ software 1.8.0 (Available online: rsb.info.nih.gov/ij).
Density value of each band was normalized against housekeeper protein GAPDH. Fold changes
(with respect to control group) were calculated as the ratio of the average of normalized densities of
each group (n per group = 2) and the average of the controls. Experiments were performed in triplicate.
4.7. HPLC Method
4.7.1. Chemicals and Reagents
All chemicals and solvents were of analytical-reagent grade and used without further purification.
Methanol HPLC grade was from VWR International, sodium acetate and 2-O-phthaldialdehyde was
from Sigma-Aldrich (St. Louis, MO, USA).
4.7.2. Samples Preparation
Brains were stored at −80 ◦C until analysis. Tissues were homogenized in 5 volumes (w/v) of
methanol: 0.1 M Perchloric Acid 1:1 and then centrifuged for 5 min at 3000× g at 4 ◦C. 40 mL of
supernatants were then used for derivatization procedure.
4.7.3. Derivatization Procedure
The standards or samples were precolumn derivatized with 2-O-phthaldialdehyde (OPA) reagent
solution. The derivatization reagent was freshly prepared every week and protected from light
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exposure, as described by Perucho in a previous study [43]. After derivatization, 35 µL of the mixture
was injected into the analytical system.
4.7.4. Chromatography System
An Agilent 1100 series HPLC system (Santa Clara, CA, USA) equipped with a Fluorescence
Detector (flow-cell volume of 8 µL) was used for this study. The detector excitation and emission
wavelengths were set at 240 and 450 nm, respectively. The Synergi Hydro-RP analytical column
(80 Å, 150 mm × 2 mm × 4 µm) was used as stationary phase at ambient temperature [44]. Gradients
were prepared with two degassed solvent mixtures. Solvent A was 0.05 M sodium acetate buffer, pH 5.88,
and methanol (95:5), and Solvent B was methanol and double-distilled water (70:30). Gradient program
was set as follows: initial conditions 25% B, linear step to 25% B from 0.1 to 3 min, gradient step to
33% B in 6.5 min, gradient step at 60% B for 2.5 min duration, jump to 25% B in 0.1 min; flow rate of
0.5 mL/min. Taurine concentration was calculated by comparison with calibrated external standard
solution (1 µM).
4.8. Statistical Analyses
Statistical analyses were performed by using computing environment R and related specific
“packages”. Graphics (plots and histograms) were generated by using GraphPad Prism (V.7)
software. Values are presented as mean ± SEM. For all statistical approaches, a p-value < 0.05 was
considered significant.
4.8.1. Behavioral Tests
Data were analyzed by fitting General Estimating Equations (GEE) [45] using “geeglm” function
(library “geepack”) with an AutoRegressive Order 1 (AR1) correlation structure and link = “identity”.
Wald χ2 tests were conducted to evaluate the effect of genotype, treatment and time point (week) and
their interactions. For each time point, individual group means were then compared using Tukey’s
method to adjust p-values. For all behavioral tests, only mice with measurements in at least three time
points were included in the analyses.
4.8.2. Neurotransmitters Dosage
To evaluate differences in neurotransmitters (Taurine, Glutamic acid, Glutamine and GABA)
levels in mouse brain and serum (only for taurine), inter-group comparisons were carried out by using
two-way ANOVA, followed by TukeyHSD post hoc test.
4.8.3. Western-Blot
Fold change differences with respect to untreated wild type group were analyzed by using a
one-way ANOVA followed by TukeyHSD post hoc test.
5. Conclusions
This study first explores and proves the therapeutic effect of the sulfur-containing amino
acid taurine, neurotransmitter agonist of GABAergic transmission involved in neurogenesis and
neuroprotection, able to rescue the motor and learning deficit in a mouse model of the rare
neurodevelopment disorder Angelman syndrome. The investigation of the involved mechanisms
pointed to a restoration of the activation of the ERK pathway and of extrasynaptic GABAergic inhibition.
The well-known role of taurine in preventing mitochondrial oxidative stress and inhibiting apoptosis
as well as the proved enhancement of adult neural stem cells might also contribute to ameliorate the
behavior deficits of AS model.
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Abbreviations
AS Angelman Syndrome
UBE3A Ubiquitin-protein ligase E3A
GABA Gamma aminobutyric acid
CNS Central nervous system
OFT Open field test
NORT Novel object recognition test
PSD-95 PostSynaptic Density-95
pERK1/2 Phospho-extracellular signal-regulated Kinase
ERK1/2 Total-extracellular signal-regulated Kinase
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
HPLC High performance liquid chromatography
Appendix A
Figure A1. Measurements of neurotransmitters in whole brains evidenced no statistical differences
between groups. HPLC experiments on whole mouse brain were carried out to quantify levels
of Glutamic acid, Glutamine and Gamma AminoButyric Acid (GABA). Number of mouse brains:
wt + vehicle = 13, wt + taurine = 3, Ube3am−/p+ + vehicle = 5, Ube3am−/p+ + taurine = 6.
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